Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, Japan.
Clin Exp Hypertens. 2009 Nov;31(8):698-704. doi: 10.3109/10641960903407066.
We have demonstrated that oxidative stress in the rostral ventrolateral medulla (RVLM), a vasomotor center in brainstem, increases sympathetic nerve activity (SNA) and that oral administration of atorvastatin inhibited SNA via anti-oxidant effect in the RVLM of stroke-prone spontaneously hypertensive rats (SHRSPs). The impairment of baroreflex sensitivity (BRS) is known as the predictive factor of mortality in the hypertension and BRS is impaired in SHRSP. The aim of the present study was to determine whether oral administration of atorvastatin improved the impaired BRS via anti-oxidant effect in the RVLM in SHRSP. Atorvastatin (20 mg/kg/day) or vehicle was orally administered for 28 days in SHRSPs. Systolic blood pressure (SBP), heart rate, and 24-h urinary norepinephrine excretion as an indicator of SNA were comparable between atorvastatin- and control-SHRSP. Thiobarbituric acid-reactive substance (TBARS) levels as a marker of oxidative stress was significantly lower in atorvastatin-SHRSP than in control-SHRSP. Baroreflex sensitivity measured by the spontaneous sequence method was significantly higher in atorvastatin-SHRSP than in control-SHRSP. These results suggest that atorvastatin improves the impaired BRS in SHRSP via its anti-oxidant effect in the RVLM of SHRSP.
我们已经证明，脑干部位的血管运动中枢——延髓头端腹外侧区（RVLM）的氧化应激会增加交感神经活动（SNA），而阿托伐他汀的口服给药通过 RVLM 中的抗氧化作用抑制了 SNA。众所周知，血压反射敏感性（BRS）的损害是高血压患者死亡率的预测因素，而 SHRSP 中的 BRS 受损。本研究的目的是确定阿托伐他汀是否通过 RVLM 中的抗氧化作用改善了 SHRSP 中受损的 BRS。阿托伐他汀（20 mg/kg/天）或载体在 SHRSP 中口服给药 28 天。阿托伐他汀-SHRSP 和对照-SHRSP 的收缩压（SBP）、心率和 24 小时尿去甲肾上腺素排泄作为 SNA 的指标相当。作为氧化应激标志物的硫代巴比妥酸反应物质（TBARS）水平在阿托伐他汀-SHRSP 中明显低于对照-SHRSP。通过自发性序列法测量的血压反射敏感性在阿托伐他汀-SHRSP 中明显高于对照-SHRSP。这些结果表明，阿托伐他汀通过其在 SHRSP 的 RVLM 中的抗氧化作用改善了 SHRSP 中受损的 BRS。
